Biogen, Eisai and Alzheimer's
Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA approved the maintenance dosing of once every four weeks after 18 months of the initiation phase of once every two weeks.
Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its ...
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback